Virus Encoded Tumoricidal Proteins

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Medicine".

Deadline for manuscript submissions: closed (15 April 2022) | Viewed by 310

Special Issue Editors

King’s College, Guy’s Hospital, London, UK
Interests: apoptin; apoptosis; prognostic biomarkers; combination therapy; head and neck cancer; tumour hypoxia
Special Issues, Collections and Topics in MDPI journals
Department of Biochemistry, Goodman Cancer Research Institute, McGill University, Montreal, Canada
Interests: Circovirus; Adenovirus; cell cycle; tumor biology; virus-host interactions

Special Issue Information

Dear Colleagues,

Viruses are known to induce massive changes in their target host cells during infection. Many seminal findings in cancer biology have emerged from the study of virology. The discovery of the Src oncogene and the Rb and p53 tumour suppressors are notable examples. In addition to furthering our understanding of tumorigenesis, viruses are also providing insights into how tumour cells can be selectively targeted for destruction. Several viruses have been demonstrated to encode proteins that can inhibit cell cycle progression or induce cell death selectively in cancer cells. In particular, proteins encoded by single-stranded DNA viruses including Circovirus, Anellovirus and Parvovirus have each been shown to express proteins with tumouricidal properties. These families of viruses have a natural tropism for dividing cells, which may in part explain their ability to target tumour cells. More complex viruses including Adenovirus, Herpesvirus and Poxviruses have also been shown to express proteins that elicit tumour-selective killing. This Special Issue of Biomolecules highlights recent advances in our understanding of the mechanism of action of this intriguing class of viral proteins and their clinical application for the treatment of cancer and other conditions.

Prof. Dr. Mahvash Tavassoli
Prof. Dr. Jose Teodoro
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Viral proteins
  • novel therapeutics
  • tumour selective cell death
  • Apoptin
  • E4-orf4
  • Circovirus
  • Adenovirus

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop